Skip to content
PubMed This is a summary of 69 peer-reviewed journal articles Updated
Neuro-oncology · Metastatic Pituitary Neuroendocrine Tumor

Pituitary Carcinoma: A Patient Guide

At a Glance

Pituitary carcinoma, now often called metastatic pituitary neuroendocrine tumor (PitNET), is a rare pituitary tumor that has spread to the brain, spine, or distant organs. A specialist team tailors care, which may include surgery, radiation, temozolomide, and hormone management.

Disclaimer: This guide provides evidence-based information for educational purposes and does not replace the advice of your treating team. If you experience sudden severe headache, new or worsening vision changes, confusion, or collapse, seek emergency medical care immediately.

A diagnosis of Pituitary Carcinoma, which the 2022 WHO classification favors calling a Metastatic Pituitary Neuroendocrine Tumor (Metastatic PitNET), represents a significant shift in your medical journey [1]. Unlike most pituitary tumors, which stay confined to the small area at the base of the brain, this condition is defined by the spread of tumor cells to other parts of the body, such as the brain, spine, or distant organs [2]. It is an exceptionally rare diagnosis, occurring in fewer than 0.2% of all pituitary cases, and often develops many years after an initial pituitary tumor was first identified [3][4].

Because of its rarity, managing this condition requires a level of specialized knowledge that goes beyond standard cancer care. The most effective approach involves a multidisciplinary team of experts—including neuro-oncologists, pituitary neurosurgeons, and specialized endocrinologists—who work together to balance tumor control with hormone management [5][6]. This collaborative effort is essential because the behavior of these tumors is highly individual. There is no single standard combination for every patient; treatment depends on the sites and pace of spread, hormone subtype, symptoms, prior treatment, and patient goals. It often involves an individualized combination of surgical decompression, targeted radiation, and systemic therapies like chemotherapy [7][8].

While the diagnosis is serious, the medical landscape for metastatic PitNET is evolving. When systemic treatment is indicated for aggressive or progressive disease, the oral chemotherapy drug temozolomide is guideline-supported first-line chemotherapy, and newer investigational options such as immunotherapy and targeted radiation are being explored in specialized centers [5][9]. Navigating this path involves consistent monitoring through imaging and blood work, but it also offers opportunities for you to advocate for the most advanced care available. By partnering with a dedicated team of specialists, you can ensure that your treatment plan is as unique as your diagnosis, focusing on both controlling the disease and maintaining your quality of life [10].

Common questions in this guide

What is pituitary carcinoma, and what does metastatic PitNET mean?
Pituitary carcinoma is the older term for a metastatic pituitary neuroendocrine tumor, or PitNET. It is defined by pituitary tumor cells spreading beyond the pituitary gland to places such as the brain, spine, or distant organs.
How rare is metastatic PitNET, and when can it appear?
Metastatic PitNET occurs in fewer than 0.2% of pituitary tumor cases. It often develops many years after an initial pituitary tumor was identified, although the timing can vary.
What specialists should be involved in treating metastatic PitNET?
Care is usually coordinated by a multidisciplinary team that may include a neuro-oncologist, pituitary neurosurgeon, and specialized endocrinologist. The team considers tumor control, hormone management, symptoms, and personal goals together.
What treatments are used for pituitary carcinoma?
There is no single treatment combination for every patient. Depending on where and how quickly the tumor has spread, the hormones involved, symptoms, previous treatment, and goals, care may combine surgery to relieve pressure, focused radiation, and medicines that work throughout the body. Temozolomide is guideline-supported first-line chemotherapy when systemic treatment is needed for aggressive or progressive disease, while immunotherapy and newer radiation approaches are being studied in specialized centers.
Which symptoms mean I should seek emergency care?
Seek emergency medical care immediately for a sudden severe headache, new or worsening vision changes, confusion, or collapse. These symptoms can have many causes, but they should not be ignored.
How can I choose a care team for metastatic PitNET?
Ask whether the hospital has a multidisciplinary tumor board that reviews metastatic pituitary tumors and how many such patients the team has managed. It is also reasonable to identify who will coordinate communication among neurosurgery, oncology, and endocrinology and to agree on goals for the next three to six months.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does our hospital have a specialized multidisciplinary tumor board that reviews cases of metastatic pituitary tumors?
  2. 2.Given the rarity of my diagnosis, how many patients with metastatic PitNET has this team managed in the last few years?
  3. 3.Who is the primary point of contact for coordinating my care between neurosurgery, oncology, and endocrinology?
  4. 4.What are our main goals for the next three to six months of treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (10)
  1. 1

    Overview of the 2022 WHO Classification of Pituitary Tumors.

    Asa SL, Mete O, Perry A, Osamura RY

    Endocrine pathology 2022; (33(1)):6-26 doi:10.1007/s12022-022-09703-7.

    PMID: 35291028
  2. 2

    Pituitary carcinoma: reclassification and implications in the NET schema.

    Asa SL, Ezzat S

    Endocrine oncology (Bristol, England) 2022; (2(1)):R14-R23 doi:10.1530/EO-22-0041.

    PMID: 37435449
  3. 3

    Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.

    Yoo F, Kuan EC, Heaney AP, et al.

    Pituitary 2018; (21(3)):290-301 doi:10.1007/s11102-018-0872-8.

    PMID: 29404894
  4. 4

    Role of Surgery in the Multimodal Treatment of Pituitary Carcinoma: A Retrospective Single-Institution Case Series.

    Faraj CA, Tran M, Ferguson SD, et al.

    Cancers 2026; (18(13)) doi:10.3390/cancers18132064.

    PMID: 42449609
  5. 5

    European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.

    Raverot G, Burman P, McCormack A, et al.

    European journal of endocrinology 2018; (178(1)):G1-G24.

    PMID: 29046323
  6. 6

    Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use.

    Iglesias P

    Journal of clinical medicine 2023; (13(1)) doi:10.3390/jcm13010116.

    PMID: 38202123
  7. 7

    Delayed Craniospinal Metastasis of Aggressive Nonfunctioning Pituitary Adenomas as Pituitary Carcinomas.

    Raghu ALB, Everson MC, Helal A, et al.

    Journal of neurological surgery. Part B, Skull base 2022; (83(Suppl 2)):e253-e259 doi:10.1055/s-0041-1725024.

    PMID: 35832993
  8. 8

    Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.

    Lamas C, Cámara R, Fajardo C, et al.

    Frontiers in endocrinology 2023; (14()):1204206 doi:10.3389/fendo.2023.1204206.

    PMID: 37720528
  9. 9

    Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study.

    Majd N, Waguespack SG, Janku F, et al.

    Journal for immunotherapy of cancer 2020; (8(2)) doi:10.1136/jitc-2020-001532.

    PMID: 33427689
  10. 10

    Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.

    Raverot G, Burman P, Abreu AP, et al.

    European journal of endocrinology 2025; (192(6)):R45-R78 doi:10.1093/ejendo/lvaf100.

    PMID: 40506054

This page about metastatic pituitary neuroendocrine tumors is for informational purposes only and does not constitute medical advice or replace your treating team’s guidance. Seek emergency care for sudden severe headache, new or worsening vision changes, confusion, or collapse.

Get notified when new evidence is published on Pituitary carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.